Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit

A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>